Published in J Cancer Res Clin Oncol on March 06, 2010
Targeting Hsp90 in urothelial carcinoma. Oncotarget (2015) 0.87
HER2 as a target in invasive urothelial carcinoma. Cancer Med (2015) 0.84
HER2 as a promising target for cytotoxicity T cells in human melanoma therapy. PLoS One (2013) 0.78
Copy number analysis of 24 oncogenes: MDM4 identified as a putative marker for low recurrence risk in non muscle invasive bladder cancer. Int J Mol Sci (2014) 0.76
Fibroblast Growth Factor Receptor 1 Overexpression Is Associated with Poor Survival in Patients with Resected Muscle Invasive Urothelial Carcinoma. Yonsei Med J (2016) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol (2007) 2.36
Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol (2006) 2.14
Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res (2001) 1.69
Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist (2008) 1.48
Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol (2009) 1.40
C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol (1996) 1.30
A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer (2009) 1.27
Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res (2001) 1.17
Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys (2005) 1.11
C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res (1995) 1.06
HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology (2004) 1.06
HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer (2003) 1.03
No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res (2008) 1.02
Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res (1995) 1.01
Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer (2002) 1.01
An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer (1992) 0.97
Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol (2003) 0.97
Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization. Oncol Rep (2008) 0.94
Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells. Int J Oncol (2009) 0.90
Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol Oncol (2007) 0.90
erbB receptor expression patterns in human bladder cancer. Urology (2005) 0.88
Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy. Urology (2007) 0.88
HER-2--a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol (2002) 0.86
Trastuzumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: report on six patients. Eur Urol (2005) 0.84
Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. Eur Urol (1991) 0.84
Long term responses with cetuximab therapy in glioblastoma multiforme. Cancer Biol Ther (2006) 1.60
Clinical role of Sm-153 EDTMP in the treatment of painful bone metastatic disease. Clin Nucl Med (2006) 0.95
Adjuvant chemotherapy for breast cancer and cognitive impairment. South Med J (2009) 0.87
Nutrition and pharyngeal cancer: results from a case-control study in Spain. Head Neck (2002) 0.83
High-throughput techniques in breast cancer: a clinical perspective. Eur J Cancer (2006) 0.82
Expression profile as predictor of relapse after adjuvant treatment in gastric cancer. J Gastrointest Cancer (2012) 0.81
Early intervention with epoetin beta prevents severe anaemia in lung cancer patients receiving platinum-based chemotherapy: a subgroup analysis of the NeoPrevent study. Lung Cancer (2007) 0.77
Complete and rapid response to FOLFIRI plus bevacizumab in a patient presenting with impaired liver function and poor performance status from colon cancer liver metastases. Anticancer Drugs (2009) 0.75
Bevacizumab: a safe and effective treatment in a patient with advanced colorectal cancer and repeated removal of metastases. Anticancer Drugs (2009) 0.75
Re: Folliculitis associated with weekly paclitaxel treatment. J Natl Cancer Inst (2003) 0.75
Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: results of the NeoPrevent study. Cancer Chemother Pharmacol (2006) 0.75